All Updates

All Updates

icon
Filter
Funding
e-therapeutics raises GBP 29 million to progress GalOmic pipeline and develop drug discovery platform
AI Drug Discovery
Jul 3, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
AI Drug Discovery

AI Drug Discovery

Jul 3, 2024

e-therapeutics raises GBP 29 million to progress GalOmic pipeline and develop drug discovery platform

Funding

  • UK-based AI drug discovery company e-therapeutics has secured GBP 28.90 million (~USD 37.9 million) in funding a round that saw participation from existing shareholders M&G Investment Management Limited and Richard Griffiths.

  • The company plans to allocate the raised funds to advance its multiple GalOmic pipeline assets toward clinical trials, further develop its HepNet computational platform, and to maintain a robust early pipeline. The company also plans to explore the option of listing on the Nasdaq in the foreseeable future.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.